CTLA4 and hematopoietic and lymphoid cell neoplasm: Over the past decade, immune checkpoint inhibitors targeting CTLA-4, PD-1,and PD-L1 have become standard of care across multiple solid tumors, while chimeric antigen receptor (CAR) T-cell therapies havedemonstrated remarkable efficacy in hematologic cancers.